Data analysis

Glory Star’s Customer Mining Method and System Awarded China National Invention Patent

Retrieved on: 
Tuesday, September 12, 2023
China National Intellectual Property Administration, Data collection, Research, Blaze of Glory (Star Trek: Deep Space Nine), Data analysis, Acquisition, Patent, Mining, AI, CHEERS

The patent, granted to Glory Star's subsidiary CHEERS, is titled "Customer Mining Method and System Based on Customer Behavioral Characteristics," which propels the Company to the forefront of technological innovation in the field of customer acquisition.

Key Points: 
  • The patent, granted to Glory Star's subsidiary CHEERS, is titled "Customer Mining Method and System Based on Customer Behavioral Characteristics," which propels the Company to the forefront of technological innovation in the field of customer acquisition.
  • This patent marks a significant milestone, underscoring Glory Star's unwavering commitment to research and development excellence.
  • It encompasses a comprehensive range of cutting-edge features, including data collection, data preprocessing and analysis, customer clustering and mining, and result visualization.
  • "We are thrilled to have achieved this national invention patent for our revolutionary Customer Mining Method and System," Mr. Bing Zhang, Chairman and CEO of the Company, commented.

New Research Indicates a Shift in What Consumers Find Memorable on Social Media

Retrieved on: 
Tuesday, September 12, 2023
Small business, Social network, Friends, Marketing, Research, CMO, Creativity, Organization, Trust, Data analysis, Social media, Publishing, AI, System, Family, Sales

With consumers primarily following brands on social media to stay up-to-date on products and services (68%), the 2023 Index reveals a shift in what consumers want on social media and makes it clear that brands must prioritize personalized care and engagement.

Key Points: 
  • With consumers primarily following brands on social media to stay up-to-date on products and services (68%), the 2023 Index reveals a shift in what consumers want on social media and makes it clear that brands must prioritize personalized care and engagement.
  • “Social media is the channel for building that trust, and consumers expect a brand’s social presence to provide authentic communication and strong customer care.
  • Furthermore, a third are concerned with maintaining a balance between AI and human touch in social media interactions, and 42% of consumers are apprehensive about brands using AI in social media interactions.
  • The majority (64%) of social media teams today are organized by specific social media platforms or networks, with one team member being responsible for TikTok, another for Instagram, etc.

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

Retrieved on: 
Monday, September 11, 2023
PD, American Neurological Association, Half-life, IGNITE, Pharmacokinetics, SAD, Biomarker, Publication, MRI, Data analysis, Magnetic resonance imaging, TREM2, Data, Patient, ANA, MAD, Microglia, CSF, CSF1R, Safety, Pharmaceutical industry, Generic drug, Medical imaging, ALSP

WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the complete data analysis from its VGL101 Phase 1 single and multiple ascending dose (SAD and MAD) healthy volunteer trial in a poster presentation at the 2023 American Neurological Association (ANA) Annual Meeting. In addition, the Company presented a poster highlighting the study design for its ongoing IGNITE Phase 2 clinical trial.

Key Points: 
  • In addition, the Company presented a poster highlighting the study design for its ongoing IGNITE Phase 2 clinical trial.
  • “The dataset from the VGL101 Phase 1 healthy volunteer trial is very encouraging and further validates our development strategy for the ongoing IGNITE Phase 2 trial in ALSP.
  • “We are committed to achieving further milestones for VGL101, including the interim data readout from IGNITE in the fourth quarter of 2023.
  • In a separate poster at the ANA Annual Meeting, the Company presented the trial design for its ongoing Phase 2 IGNITE trial.

GBT Receives Patent Grant Notification Covering its Integrated Circuits Reliability Verification Analysis and Auto-Correction Technology

Retrieved on: 
Thursday, September 7, 2023
Patent, U.S. Patent No. 1, Epsilon, Overheating, EDA, IC, Research, Pulse, Data analysis, Machine learning, SAN, Algorithm, OTC, Physics, GBT, Printed circuit board

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT” or the “Company”), received a grant notification for its microchip’s reliability verification and auto-correction EDA patent application, internal project’s code name, Epsilon. The patent will be granted as U.S. Patent No. 11,763,062 on September 19, 2023. GBT’s Epsilon patent application covers the innovative technology to address advanced semiconductor node physics with the goal of ensuring a high level of reliability, optimal thermal design, lower power consumption and high performance. The described technology includes machine learning algorithms to enable robust design, process optimization, characterization, modeling, and simulation. The technology underlying the patent identifies reliability flaws, describes the found issues, and allows an automatic correction of these reliability issues early during the IC’s design phase. Machine Learning techniques will be performing data analysis, identification, categorization, and reasoning about executing the optimal IC layout automatic correction. The technology aims to allow IC designers to analyze and fix circuits early during the design phase in real time with the goal of creating higher efficiencies. GBT plans to continue its R&D efforts in this domain, inventing modern technologies and enabling reliable, low-power, high-performance, next-generation microchips.

Key Points: 
  • The Patent is scheduled for Grant on September 19, 2023
    SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK: GTCH ) ("GBT” or the “Company”), received a grant notification for its microchip’s reliability verification and auto-correction EDA patent application, internal project’s code name, Epsilon.
  • The described technology includes machine learning algorithms to enable robust design, process optimization, characterization, modeling, and simulation.
  • The technology underlying the patent identifies reliability flaws, describes the found issues, and allows an automatic correction of these reliability issues early during the IC’s design phase.
  • Our Epsilon patent is an intelligent design productivity enhancement EDA software solution that analyzes, detects, and eliminates electrical reliability issues on-the-fly.

NanoString to Host Virtual Spatial Genomics Summit September 19

Retrieved on: 
Thursday, September 14, 2023
Research, Other Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Health, Other Science, Inflammation, Product management, University College London, Drug development, IBD, DSP, Griffith University, SMI, MicroRNA, Gene expression, Biomarker, WTA, Proteomics, Information, IPA, Protein, Data analysis, MD, Data, NanoString Technologies, Biology, Inflammatory bowel disease, Ecosystem, Northwestern University, Gene, Medical imaging, Microscope, Medicine

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced it will host its fifth annual Spatial Genomics Summit , September 19th.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced it will host its fifth annual Spatial Genomics Summit , September 19th.
  • “The Spatial Genomics Summit is an educational forum for showcasing hot-off-the-press datasets and breakthrough applications,” said Joe Beechem, Chief Scientific Officer of NanoString.
  • Joseph Beechem, Ph.D. Chief Scientific Officer, NanoString: Spatial Biology Roadmap: Transforming the Information Content Obtained from a Single Tissue Section.
  • The NanoString logo, NanoString, NanoString Technologies, GeoMx, CosMx, AtoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.

Aware Unveils Advanced Automated Workflows to Ignite Collaboration Platforms

Retrieved on: 
Wednesday, September 13, 2023
Data Management, Technology, Professional Services, Business, Security, Data Analytics, Software, Artificial Intelligence, Other Professional Services, Legal, Human Resources, Cisco Webex, Heart, Experience management, Natural language processing, Microsoft Teams, Risk, Workflow, CV, GRC, Zendesk, Work, WorkJam, Intelligence, Microsoft, Human, Toxicity, Computer vision, NLP, Asana, Organization, Data analysis, Cisco, Zoom, Context, DEX, Natural language, Sales, Management, Atlassian, Computer security

Aware, the AI Data Platform for powering enterprise workflow, today announced the launch of its comprehensive automated workflows, designed to supercharge enterprise workflows with AI-powered insights.

Key Points: 
  • Aware, the AI Data Platform for powering enterprise workflow, today announced the launch of its comprehensive automated workflows, designed to supercharge enterprise workflows with AI-powered insights.
  • According to Aware’s Future of Work Research Series, which analyzed over 6 billion collaboration messages, Slack and other collaboration platforms are the hub of the new enterprise workflow.
  • Employees spend approximately 57% of their day using these platforms, sending over 18 trillion messages in 2022—double the volume from the previous year.
  • With these workflows, Aware is closing the gap between data analysis and decision making, empowering teams to identify and act on emerging opportunities like never before.

Heap Delivers Solutions at Speed for Enterprises of Any Size and Complexity

Retrieved on: 
Tuesday, September 12, 2023
Professional Services, Data Management, Data Analytics, Technology, Software, Networks, Internet, Data collection, Pain, Data analysis, Privacy, CPO, Retail, Heap

The new capabilities allow enterprises to understand actions users take across all platforms.

Key Points: 
  • The new capabilities allow enterprises to understand actions users take across all platforms.
  • Heap’s platform can be leveraged by enterprises across the globe or start-ups of any size.
  • Companies of any size can access meaningful data and achieve speed to insight,” said Rachel Obstler, CPO of Product at Heap.
  • To see what Heap can do for your company’s data needs, sign up for a platform demo here .

Leading the Way: North America Maintains Dominance in the Global 3D Mapping and Modeling Market - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 12, 2023
Other Construction & Property, Architecture, Technology, Construction & Property, Software, Lead, SLAM, 3D, Geographic information system, Research, USD, App Store (iOS/iPadOS), Entertainment, VR, Lidar, Row, Data analysis, Photogrammetry, Animation, Growth, Environment, AR, GIS, 3D printing, Medical imaging

The surge in 3D content availability, coupled with the advent of 3D-enabled display devices, is priming the 3D mapping and modeling market for growth.

Key Points: 
  • The surge in 3D content availability, coupled with the advent of 3D-enabled display devices, is priming the 3D mapping and modeling market for growth.
  • As the market matures, solution providers are expected to enhance user experiences, innovate industry-specific tools, and push the limits of 3D mapping and modeling capabilities.
  • North America Dominates: North America is at the forefront of technological progress in the 3D mapping and modeling market.
  • The region's robust infrastructure and widespread connectivity provide a solid foundation for expanding 3D mapping and modeling solutions.

Palantir Technologies Signs Partnership With Titan Defence Firm, Babcock

Retrieved on: 
Wednesday, September 13, 2023
Data Management, Defense, Security, Technology, Software, Artificial Intelligence, Contracts, Partnership, AIP, Indian Army Public Schools, Equipment support, Defence Support Group, DSEI, EA, Palantir Technologies, Carbon, Ship, Babcock, DSG, Babcock International, Microsoft Enterprise Agreement, Data analysis, PLTR, Nature, European, Daou Technology Inc., Ecosystem, Royal College of Defence Studies, Maintenance, UK, News, NYSE, MOD, Sales, Arms industry, Risk management, Land, Palantir

Palantir Technologies Inc. (NYSE: PLTR) is enabling the Babcock International Group to strengthen its digital defence capabilities through an Enterprise Agreement (EA) announced at DSEI today in London.

Key Points: 
  • Palantir Technologies Inc. (NYSE: PLTR) is enabling the Babcock International Group to strengthen its digital defence capabilities through an Enterprise Agreement (EA) announced at DSEI today in London.
  • The partnership will leverage Palantir AIP, the AI-enabled instance of the company’s software, that will aim to transform how the Babcock workforce captures, integrates, models and builds data-driven solutions.
  • Guy Williams, Head of UK Defence & National Security from Palantir Technologies said:
    “We’re excited to partner with Babcock as they realise their digital defence ambitions.
  • Together, we are driving toward a new era for the UK’s Defence enterprise - one that is pioneering, modern and leverages Palantir AIP.

Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress

Retrieved on: 
Monday, September 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Partnership, Therapy, Impact, Food, PARP2, WRN, PARP1, EDT, Trial of the century, Science, Data analysis, Patient, Automation, Machine learning, TLR 7, Engineering, Eikon, Drug discovery, Morgan, AI, TLR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, VCP, Antiandrogen, Pharmaceutical industry, IND

“Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.

Key Points: 
  • “Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.
  • “Our advanced analytical tools have enabled Eikon to capitalize on near-term opportunities to bring new medicines to patients.
  • Eikon believes that adverse experiences associated with BDB001 treatment are manageable using Eikon’s proposed clinical dosing regimen.
  • Eikon anticipates initiating Phase 1 clinical studies of IMP1734 in the United States and other jurisdictions in the fourth quarter.